Aseptic Fill Finish Manufacturing Market

Aseptic Fill Finish Manufacturing Market by Type of Molecule, Type of Packaging Container Offered, Type of Drug Product, Scale of Operation, Company Size, Target Therapeutic Area and Geographical Regions: Industry Trends and Global Forecasts, 2023-2035

Lowest Price Guaranteed From USD 4,799
Published
March 2023
Pages
270
View Count
9264
Buy Now

Example Insights

Please refer below for insights

Report Description

Aseptic Fill Finish Manufacturing Market Overview

The aseptic fill finish manufacturing market is estimated to be worth USD 5.4 billion in 2023 and is expected to grow at compounded annual growth rate (CAGR) of 9%, during the forecast period. Aseptic fill finish refers to accurate and sterile fill finish / sealing of drug products into packaging containers, such as vials, prefilled syringes, ampoules and cartridges. These aseptic conditions during fill-finish operations are not only essential for ensuring end-user’s safety, but also maintaining pharmacological efficacy and product quality. It is worth noting that aseptic fill finish manufacturing requires skilled personnel, specialized automated equipment, clean room setup and continuous supervision to maintain the sterility and safety of the final drug product. However, given the high cost of specialized equipment and affiliated expertise required for fill-finish operations, it is difficult for a drug developer with limited finances and capacity constraints to meet the needs of their clientele. As a result, various stakeholders are outsourcing their fill finish manufacturing related needs to contract service providers, in order to ensure the development of quality drug products. In fact, a number of companies are involved in offering services for aseptic fill finish of a wide range of biologics and small molecules. Additionally, there is a need for expanding the capacity to meet the anticipated demand for such operations. For this purpose, service providers have inked several agreements over the last few years. Driven by the consistent initiatives being undertaken by companies in this industry, the aseptic fill finish manufacturing market is anticipated to grow at a steady pace, over the forecast period.

Key Market Insights

The Aseptic Fill Finish Manufacturing Market by Type of Molecule (Small Molecules and Biologics), Type of Packaging Container Offered (Ampoules, Cartridges, Prefilled Syringe and Vials), Type of Drug Product (Antibodies, Cell Therapies, Gene Therapies, Oligonucleotides, Recombinant Proteins, Vaccines and Other Products), Scale of Operation (Preclinical / Clinical and Commercial), Company Size (Large, Mid-sized and Small), Target Therapeutic Area (Autoimmune Disorders, Cardiovascular Disorders, Infectious Diseases Oncological Disorders, and Other Disorders) and Geographical Regions (North America, Europe, Asia Pacific, Middle East and North Africa and Latin America): Industry Trends and Global Forecasts, 2023-2035 report features an extensive study of the current market landscape, market size and future opportunity for the aseptic fill finish service providers. Some of the key takeaways from the market report are mentioned below.

Growing Demand for Aseptic Fill Finish Services

Aseptic fill finish is a critical step in the production of drugs, as it involves the aseptic fill and finish of therapeutic products into containers. In fact, even a minute error during the fill finish manufacturing process can lead to microbial contamination, posing a considerable risk to the patient’s health. Therefore, aseptic fill finish operations need to be performed under controlled environmental conditions, in order to minimize the exposure of drug product to factors that could negatively impact its stability and efficacy. This, in turn, helps in extending the shelf life of a drug product. It is also worth mentioning that, in recent years, many players are carrying out fill-finish operations using automated equipment, without any manual intervention. This practice is believed to enhance the production efficiency, minimize downtime, reduce waste production, as well as increase the overall productivity. ,

Fill Finish CMO: Need for Outsourcing Aseptic Fill Finish Operations

The growing demand for pharmaceutical and biopharmaceutical drug products has created a need for higher capacity for production of therapies and their corresponding sterile fill finish operations. However, extensive capital investment and complex infrastructure is necessary for carrying out in-house fill&finish of biologics and small molecules. In addition, mishandling of drug product during the fill-finish process can lead to microbial contamination, which can subsequently result in the loss of drug product, production delays and most importantly, pose a risk to the patient’s health. These aforementioned challenges have prompted pharmaceutical drug developers to outsource their sterile fill finish operations to service providers, which have the required fill finish facility and specialized equipment to ensure the quality of end products. With the growing demand for biologics and the advent of new generation of complex biologics and ATMPs, the aseptic fill finish manufacturing market for the contract manufacturers will continue to witness healthy market growth over the forecast period.

Sterile Fill Finish: Key Drivers of the Aseptic Fill Finish Manufacturing Market

At present, the rising demand for outsourcing of aseptic fill finish services is driven by multiple factors, such as growing pipeline of drug products, stringent regulatory requirements, in-house capacity constraints, technological advancements and increased awareness related to the benefits of aseptic fill finish services.

Current Market Landscape of Aseptic Fill Finish Service Providers

The current market landscape features the presence of over 235 aseptic fill finish service providers, spread across the globe. Overall, the market seems to be well-fragmented, featuring the presence of large, mid-sized and small companies, which have the required expertise to offer aseptic fill finish services across different types of packaging containers such as pharmaceutical vials and prefilled syringe. Additionally, various recent developments in this segment of the pharmaceutical industry indicate that service providers are actively upgrading their sterile fill finish capabilities and infrastructure to accommodate the current and anticipated demand for aseptic fill finish services.

Aseptic Fill Finish Manufacturing: Overall Market Size is Anticipated to Increase at CAGR of ~9%

Driven by the growing pipeline of pharmaceutical and biopharmaceutical drug products, as well as the rising demand for contract manufacturing in this sector, the aseptic fill finish manufacturing market is anticipated to grow at a CAGR of 9%, during the forecast period. Specifically, in terms of type of packaging container, the highest market share is anticipated to be captured by vials and prefilled syringe. In addition, at present, a major proportion of the market is represented by players based in North America and Europe. However, over the forecast period, Asia Pacific market is anticipated to grow at a higher CAGR.

Key Companies in the Aseptic Fill Finish Manufacturing Market

Examples of key companies engaged in offering sterile fill finish services for biologics and small molecules include (which have been captured in this report) Aenova, AbbVie Contract Manufacturing, APL, Asymchem, BioPharma Solutions, BioReliance, Boehringer Ingelheim BioXcellence, Catalent Biologics, Charles River Laboratories, CordenPharma, Delpharm, Fareva, Fresenius Kabi, Glaxo SmithKline, Hetero Drugs, Intas Pharmaceuticals, Lonza, Pierre Fabre, Patheon, Pfizer CentreOne, Plastikon Healthcare, PiSA Farmaceutica, Recipharm, Sharp Services, Wacker Biotech, Syngene, Takara Bio, WuXi Biologics, Siegfried and Wockhardt. This market report includes an easily searchable excel database of all the aseptic fill finish CMO worldwide.

Recent Developments in Aseptic Fill Finish Market

Several recent developments have taken place in the field of aseptic fill finish market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

In June 2023, WuXi announced the expansion of its capacity for drug substance and drug product in Germany.
In May 2023, Moderna collaborated with Novocol Pharma in order to perform aseptic fill-finish, labelling and packaging of mRNA respiratory vaccines in Canada.

Scope of the Report

The market report presents an in-depth analysis of the various firms / organizations that are engaged in this industry, across different segments, as defined in the below table:

Key Report Attributes	Details
Base Year	2022
Forecast Period	2023-2035
Historical Period	2018-2022
Market Size 2023	$5.4 billion
CAGR	~9%
Type of Molecules	Small Molecules, Biologics
Type of Packaging Containers Offered	Vials, Syringes, Ampoules, Cartridges
Type of Drug Products	Vaccine, Recombinant Proteins, Antibodies, Oligonucleotides, Gene Therapies, Cell Therapies, Other Products
Target Therapeutic Area	Autoimmune Disorders, Cardiovascular Disorders , Infectious Disorders, Oncological Disorders , Other Disorders
Scale of Operation	Preclinical / Clinical, Commercial
Company Size	Large, Mid-sized, Small
Geography	North America, Europe, Asia Pacific, Middle East and North Africa, Latin America
Key Companies Profiled	AbbVie Contract Manufacturing, Asymchem , Aenova , APL, BioPharma Solutions, BioReliance, Boehringer Ingelheim BioXcellence, Catalent Biologics, Charles River Laboratories , CordenPharma, Delpharm, Fareva, Fresenius Kabi, Glaxo SmithKline, Hetero Drugs, Intas Pharmaceuticals, Lonza, Pierre Fabre, Pfizer CentreOne, Plastikon Healthcare, Patheon, PiSA Farmaceutica, Recipharm, Wacker Biotech, Syngene, Sharp Services, Siegfried, Takara Bio, WuXi Biologics, Wockhardt (Full list of 235+ companies captured in the market landscape analysis of the report)
Customization Scope	15% Free Customization Option
PowerPoint Presentation (Complimentary)	Available
Excel Data Packs (Complimentary)	Market Landscape Analysis, Developers Landscape Analysis, Partnership and Collaboration Analysis, Market Forecast and Opportunity Analysis

The market report also presents an in-depth analysis of various stakeholders contributing to the aseptic fill finish manufacturing market growth, highlighting their capabilities across different geographies. Amongst other elements, the market report includes :

A summary of the key insights derived from our research, which offers a high-level view on the likely evolution of the fill finish CMO market in the short to mid-term, and long term.
A general introduction to pharmaceuticals and contract manufacturing, which features a detailed discussion on the need for outsourcing within the pharmaceutical industry and key operations outsourced by biologic and small molecule drug developers, including fill-finish. It also provides information on the key considerations for selecting a fill finish CMO, along with the advantages and risks posed by outsourcing fill&finish operations.
A detailed assessment of the overall landscape of sterile fill finish service providers, along with information on several relevant parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, type of molecule(s) (biologics and small molecules) and type of packaging container(s) offered (ready to use cartridges, ready to use prefilled syringe and ready to use vials).
A review of the overall landscape of companies offering aseptic fill finish services for biologics, along with analyses on a number of relevant parameters, such as year of establishment, company size, location of headquarters, location of fill finish manufacturuing facility, type of packaging container(s) used (ampoules, cartridges,prefilled syringe and vials), type of biologic(s) manufactured (antibody drug conjugates, antibodies, biosimilars, cell therapies, gene therapies, oligonucleotides, peptides / proteins, vaccines, viral products, and others), scale of operation (preclinical, clinical and commercial) and type of additional drug product-related service(s) offered (lyophilization, labeling, quality testing, storage and distribution services).
A detailed assessment of the overall market landscape of the companies offering aseptic fill finish services for small molecules, along with analyses on a number of relevant parameters, such as year of establishment, company size, location of headquarters, location of fill&finish manufactruing facility, type of filling service(s) offered (aseptic filling, terminal sterilization and blow fill seal services), type of finishing service(s) offered (inspection and labelling and packaging), type of packaging container(s) offered (ampoules, cartridges, prefilled syringe and vials), scale of operation (preclinical, clinical and commercial), types of dosage forms filled (solid, liquids, lyophilized products / powders and semi-solids), type of process(es) (automated and manual / semi-automated).
Tabulated profiles of key companies based in North America, Europe and Asia Pacific. Each profile provides a company snapshot, along with information on its services offered, fill-finish manufactruing facility, financial information (if available), recent developments and an informed future outlook.
A detailed analysis of the various partnerships and collaborations established by contract manufacturing organizations in aseptic fill finish manufacturing market, since 2013. It includes a brief description of different agreement models (including service agreements, service alliances, product integration agreements, joint ventures and acquisitions) adopted by service providers in this market. Further, it comprises of analysis based on year of partnership, type of partnership, scale of operation, type of molecule(s), type of service(s) offered, type of process(es) involved, and type of drug product(s) filled. It also highlights the most active companies (in terms of number of partnerships) in the industry.
A case study focused on use of robotic systems in aseptic fill and finish operations. It provides a list of equipment used by fill-finish service providers (wherever specified), highlighting the purpose of robotics in various manufacturing operations. It also includes a list of companies offering robots for use in the manufacturing processes which are carried in the pharmaceutical sector.
A case study on use of ready-to-use packaging components in aseptic fill finish operations. The chapter also provides information related to the advantages and disadvantages of ready-to-use packaging components, along with a list of suppliers providing these components.

One of the key objectives of this market report was to estimate the current market size and future opportunities in the aseptic fill finish manufacturing market, over the forecast period. We have provided an informed estimate of the likely evolution of the aseptic fill finish manufacturing market in the short to mid-term and long term, for the forecast period. In order to provide a detailed future outlook, year-wise projections of the current and future opportunity have been further segmented on the basis of type of molecule (small molecules and biologics), type of packaging container offered (ampoules, cartridges, prefilled syringe and vials), type of drug product (antibodies, cell therapies, gene therapies, oligonucleotides, recombinant proteins, vaccines and other drug products), target therapeutic area (autoimmune disorders, oncological disorders, cardiovascular disorders, infectious diseases and other disorders), scale of operation (preclinical / clinical and commercial), company size (large, mid-sized and small) and geography, (North America, Europe, Asia Pacific, Middle East and North Africa, and Latin America). To account for uncertainties in the market growth and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in this market report are backed by our understanding of key data generated from both secondary and primary research. The perceptions presented in this study were also influenced by our discussions with senior stakeholders in the industry. The report further features detailed transcripts of interviews held with the following industry and non-industry players:

Gregor Kawaletz (Former Chief Commercial Officer, IDT Biologika)
Matt Delaney (Former Vice President Business Development & Marketing, ‎Cytovance Biologics)
Purushottam Singnurkar (Vice President and Head of Formulation Development, Syngene International)
Ales Sima (Head of Business Development, Oncomed Manufacturing)
Amit Chandra (Former Technology Watch Manager, Yposkesi)
Jos Vergeest (International Business Developer, HALIX)

All actual figures have been sourced and analyzed from publicly available forums and primary research discussions. It is important to highlight that, financial figures mentioned in this report are in USD, unless otherwise specified.

Frequently Asked Questions

Question 1: What is the aseptic fill finish?

Answer: Fill finish is the last step in the aseptic manufacturing process, where drug products are filled and packaged in various packaging containers, such as vials, syringes, ampoules and cartridges, under sterile conditions. Further, the process is carried out in a controlled cleanroom environment, which has low levels of particulate matter and microorganisms to prevent microbial contamination. It is worth mentioning that fill finish is a complex and highly regulated process, to ensure the safety and efficacy of these drug products, as any contamination could lead to serious health risks for patients.

Question 2: What are the requirements and considerations for aseptic fill finish operation?

Answer: Aseptic filling process requires close coordination and complex interactions between supporting personnel and key operational equipment, sterilized drug product, cleanroom and other supporting facilities, and ancillary materials.

Question 3: How many players are providing aseptic fill finish services?

Answer: Presently, more than 235 companies offer aseptic fill finish and other related services (such as aseptic filling, terminal sterilization and blow-fill-seal).

Question 4: What are the latest trends in aseptic fill finish services market?

Answer: Aseptic fill finish market is evolving to meet the growing demands of the pharmaceutical and biopharmaceutical industry. Advanced technologies, such as robotics and single-use systems are being adopted to improve the accuracy, efficiency and safety of aseptic fill finish procedures. In fact, single-use technology reduces the risk of cross-contamination and need for cleaning validation. Further, automated aseptic filling systems reduce the human interference and can meet various operational requirements, from loading of raw material to cleaning of the equipment. This, in turn, can improve the consistency and quality of the final product.

Question 5: What is the growth rate of aseptic fill finish services market?

Answer: The global aseptic fill finish services market is expected to grow at a CAGR of 7%, during the period 2023-2035.

Question 6: Which region captures the largest share of the aseptic fill finish services market?

Answer: Currently, Europe contributes to more than 35% share of the overall market. Further, Asia-Pacific is likely to grow at a relatively faster pace, during the forecast period.

Question 7: Which segment, in terms of type of molecule, currently accounts for the largest share of the aseptic fill finish services market?

Answer: The small molecules segment currently holds the largest share (68%) in the overall aseptic fill finish services market. This trend is unlikely to change during the forecast period.

Question 8: Which types of packaging containers are most widely used in the aseptic fill finish services market?

Answer: Presently, the vials (67%) account for the largest share in the global aseptic fill finish services market.

Question 9: What type of partnerships are taking place in the aseptic fill finish services market?

Answer: At present, service agreements represent the most preferred type of partnership model adopted by stakeholders in this domain. This is followed by acquisitions and service alliances.

Contents

1. PREFACE
1.1. Chapter Overview
1.2. Key Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Contract Manufacturing
3.3. Commonly Outsourced Operations in Biopharmaceutical Industry
3.3.1. Aseptic Fill Finish Operations
3.4. Basic Guidelines for Selecting a Fill Finish Service Provider
3.5. Advantages of Outsourcing Fill Finish Operations
3.6. Risks and Challenges Associated with Outsourcing Fill Finish Operations
3.7. Concluding Remarks

4. ASEPTIC FILL FINISH SERVICE PROVIDERS LANDSCAPE
4.1. Chapter Overview
4.2. Aseptic Fill / Finish: Service Providers Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Type of Molecule(s)
4.2.5. Analysis by Type of Packaging Container(s) Offered

5. BIOLOGICS FILL FINISH SERVICE PROVIDERS LANDSCAPE
5.1. Chapter Overview
5.2. Biologics Fill Finish: Service Providers Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Location of Fill Finish Facilities
5.2.5. Analysis by Type of Packaging Container(s) Offered
5.2.6. Analysis by Type of Drug Product(s) Involved
5.2.7. Analysis by Scale of Operation
5.2.8. Analysis by Additional Drug Product-related Services Offered
5.2.9. Information on Fill Finish Capacity

6. SMALL MOLECULE FILL FINISH SERVICE PROVIDERS LANDSCAPE
6.1. Chapter Overview
6.2. Small Molecule Fill Finish: Service Providers Landscape
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Company Size
6.2.3. Analysis by Location of Headquarters
6.2.4. Analysis by Location of Fill Finish Facilities
6.2.5. Analysis by Type of Filling Service(s) Offered
6.2.6. Analysis by Type of Finishing Service(s) Offered
6.2.7. Analysis by Type of Packaging Container(s) Offered
6.2.8. Analysis by Scale of Operation
6.2.9. Analysis by Type of Dosage Form(s) Filled
6.2.10. Analysis by Type of Process(es)
6.2.11. Information on Fill Finish Capacity

7. COMPANY PROFILES: ASEPTIC FILL / FINISH SERVICE PROVIDERS IN NORTH AMERICA
7.1. Chapter Overview
7.2. Companies Offering Aseptic Fill Finish Services for Biologics
7.2.1. AbbVie Contract Manufacturing
7.2.1.1. Company Snapshot
7.2.1.2. Financial Information
7.2.1.3. Service Portfolio
7.2.1.4. Fill Finish Services Offered
7.2.1.5. Recent Developments and Future Outlook

7.2.2. BioPharma Solutions
7.2.2.1. Company Snapshot
7.2.2.2. Financial Information
7.2.2.3. Service Portfolio
7.2.2.4. Fill Finish Services Offered
7.2.2.5. Recent Developments and Future Outlook
7.2.3. BioReliance
7.2.3.1. Company Snapshot
7.2.3.2. Financial Information
7.2.3.3. Service Portfolio
7.2.3.4. Fill Finish Services Offered
7.2.3.5. Recent Developments and Future Outlook
7.2.4. Catalent Biologics
7.2.4.1. Company Snapshot
7.2.4.2. Financial Information
7.2.4.3. Service Portfolio
7.2.4.4. Fill Finish Services Offered
7.2.4.5. Recent Developments and Future Outlook
7.2.5. Charles River Laboratories
7.2.5.1. Company Snapshot
7.2.5.2. Financial Information
7.2.5.3. Fill Finish Services Offered
7.2.5.4. Recent Developments and Future Outlook
7.2.6. Patheon
7.2.6.1. Company Snapshot
7.2.6.2. Financial Information
7.2.6.3. Service Portfolio
7.2.6.4. Fill Finish Services Offered
7.2.6.5. Recent Developments and Future Outlook
7.3. Companies Offering Aseptic Fill Finish Services for Small Molecules
7.3.1.1. Pfizer CentreOne
7.3.1.2. Company Snapshot
7.3.1.3. Service Portfolio
7.3.1.4. Fill Finish Services Offered
7.3.1.5. Recent Developments and Future Outlook
7.3.2. Plastikon Healthcare
7.3.2.1. Company Snapshot
7.3.2.2. Service Portfolio
7.3.2.3. Fill Finish Services Offered
7.3.2.4. Recent Developments and Future Outlook
7.3.3. Sharp Services
7.3.3.1. Company Snapshot
7.3.3.2. Service Portfolio
7.3.3.3. Fill Finish Services Offered
7.3.3.4. Recent Developments and Future Outlook

8. COMPANY PROFILES: ASEPTIC FILL FINISH SERVICE PROVIDERS IN EUROPE
8.1. Company Overview
8.2. Companies Offering Aseptic Fill Finish Services for Biologics
8.2.1. Boehringer Ingelheim BioXcellence
8.2.1.1. Company Snapshot
8.2.1.2. Financial Information
8.2.1.3. Service Portfolio
8.2.1.4. Fill Finish Services Offered
8.2.1.5. Recent Developments and Future Outlook
8.2.2. Fareva
8.2.2.1. Company Snapshot
8.2.2.2. Fill Finish Services Offered
8.2.2.3. Recent Developments and Future Outlook
8.2.3. GlaxoSmithKline
8.2.3.1. Company Snapshot
8.2.3.2. Financial Information
8.2.3.3. Fill Finish Services Offered
8.2.3.4. Recent Developments and Future Outlook
8.2.4. Lonza
8.2.4.1. Company Snapshot
8.2.4.2. Financial Information
8.2.4.3. Service Portfolio
8.2.4.4. Fill Finish Services Offered
8.2.4.5. Recent Developments and Future Outlook
8.2.5. Pierre Fabre
8.2.5.1. Company Snapshot
8.2.5.2. Financial Information
8.2.5.3. Service Portfolio
8.2.5.4. Fill Finish Services Offered
8.2.5.5. Recent Developments and Future Outlook
8.2.6. Wacker Biotech
8.2.6.1. Company Snapshot
8.2.6.2. Financial Information
8.2.6.3. Service Portfolio
8.2.6. 4. Fill Finish Services Offered
8.2.6.5. Recent Developments and Future Outlook
8.3. Companies Offering Aseptic Fill Finish Services for Small Molecules
8.3.1. Aenova
8.3.1.1. Company Snapshot
8.3.1.2. Financial Information
8.3.1.3. Service Portfolio
8.3.1.4. Fill Finish Services Offered
8.3.1.5. Recent Developments and Future Outlook
8.3.2. APL
8.3.2.1. Company Snapshot
8.3.2.2. Service Portfolio
8.3.2.3. Fill Finish Services Offered
8.3.2.4. Recent Developments and Future Outlook
8.3.3 CordenPharma
8.3.3.1. Company Snapshot
8.3.3.2. Service Portfolio
8.3.3.3. Fill Finish Services Offered
8.3.3.4. Recent Developments and Future Outlook
8.3.4. Delpharm
8.3.4.1. Company Snapshot
8.3.4.2. Service Portfolio
8.3.4.3. Fill Finish Services Offered
8.3.4.4. Recent Developments and Future Outlook
8.3.5 PiSA Farmaceutica
8.3.5.1. Company Snapshot
8.3.5.2. Service Portfolio
8.3.5.3. Fill Finish Services Offered
8.3.5.4. Recent Developments and Future Outlook
8.4 Companies Offering Aseptic Fill Finish Manufacturing for Biologics and Small Molecules
8.4.1 Fresenius Kabi
8.4.1.1. Company Snapshot
8.4.1.2 Financial Information
8.4.1.3. Service Portfolio
8.4.1.4. Fill Finish Services Offered
8.4.1.5. Recent Developments and Future Outlook
8.4.2 Recipharm
8.4.2.1. Company Snapshot
8.4.2.2. Financial Information
8.4.2.3. Service Portfolio
8.4.2.4. Fill Finish Services Offered
8.4.2.5. Recent Developments and Future Outlook

9. COMPANY PROFILES: ASEPTIC FILL FINISH SERVICE PROVIDERS IN ASIA-PACIFIC
9.1 Company Overview
9.2 Companies Offering Aseptic Fill Finish Services for Biologics
9.2.1 Asymchem
9.2.1.1. Company Snapshot
9.2.1.2. Financial Information
9.2.1.3. Service Portfolio
9.2.1.4. Fill Finish Services Offered
9.2.1.5. Recent Developments and Future Outlook
9.2.2. Samsung Biologics
9.2.2.1. Company Snapshot
9.2.2.2. Financial Information
9.2.2.3. Service Portfolio
9.2.2.4. Fill Finish Services Offered
9.2.2.5. Recent Developments and Future Outlook
9.2.3. Syngene
9.2.3.1. Company Snapshot
9.2.3.2. Financial Information
9.2.3.3. Service Portfolio
9.2.3.4. Fill Finish Services Offered
9.2.3.5. Recent Developments and Future Outlook
9.2.4. Takara Bio
9.2.4.1. Company Snapshot
9.2.4.2. Financial Information
9.2.4.3. Service Portfolio
9.2.4.4. Fill Finish Services Offered
9.2.4.5. Recent Developments and Future Outlook
9.2.5. WuXi Biologics
9.2.5.1. Company Snapshot
9.2.5.2. Financial Information
9.2.5.3. Service Portfolio
9.2.5.4. Fill Finish Services Offered
9.2.5.5. Recent Developments and Future Outlook
9.2.6. Hetero Drugs
9.2.6.1. Company Snapshot
9.2.6.2. Fill Finish Services Offered
9.2.6.3. Recent Developments and Future Outlook
9.2.7. Intas Pharmaceuticals
9.2.7.1. Company Snapshot
9.2.7.2. Fill Finish Services Offered
9.2.7.3. Recent Developments and Future Outlook
9.3. Companies Offering Aseptic Fill Finish Services for Small Molecules
9.3.1. Siegfried
9.3.1.1. Company Snapshot
9.3.1.2. Financial Information
9.3.1.3. Service Portfolio
9.3.1.4. Fill Finish Services Offered
9.3.1.5. Recent Developments and Future Outlook
9.3.2. Wockhardt
9.3.2.1. Company Snapshot
9.3.2.2. Financial Information
9.3.2.3. Service Portfolio
9.3.2.4. Fill Finish Services Offered
9.3.2.5. Recent Developments and Future Outlook

10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Aseptic Fill Finish Service Providers: List of Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Scale of Operation
10.3.4. Analysis by Type of Molecule(s) Involved
10.3.5. Analysis by Type of Service(s) Offered
10.3.6. Analysis by Type of Process(es) Involved
10.3.7. Analysis by Type of Drug Product(s) Involved
10.3.8. Most Active Players: Analysis by Number of Partnerships
10.3.9. Analysis by Geography
10.3.9.1. Intercontinental and Intracontinental Agreements

11. MARKET SIZING AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Forecast Methodology
11.3. Overall Aseptic Fill Finish Manufacturing Market, 2023-2035
11.3.1. Aseptic Fill Finish Services Market: Analysis by Type of Molecule, 2023-2035
11.3.2. Aseptic Fill Finish Manufacturing Market: Analysis by Type of Packaging Container Offered, 2023-2035
11.3.3. Aseptic Fill Finish Manufacturing Market: Analysis by Type of Drug Product, 2023-2035
11.3.4. Aseptic Fill Finish Manufacturing Market: Analysis by Target Therapeutic Area, 2023-2035
11.3.5. Aseptic Fill Finish Manufacturing Market: Analysis by Scale of Operation, 2023-2035
11.3.6. Aseptic Fill Finish Manufacturing Market: Analysis by Company Size, 2023-2035
11.3.7. Aseptic Fill Finish Manufacturing Market: Analysis by Geography, 2023-2035
11.4. Aseptic Fill Finish Manufacturing Market for Biologics, 2023-2035
11.4.1. Aseptic Fill Finish Manufacturing Market for Biologics: Analysis by Type of Packaging Container Offered, 2023-2035
11.4.2. Aseptic Fill Finish Manufacturing Market: Analysis by Type of Drug Product, 2023-2035
11.4.3. Aseptic Fill Finish Manufacturing Market for Biologics: Analysis by Target Therapeutic Area, 2023-2035
11.4.4. Aseptic Fill Finish Manufacturing Market for Biologics: Analysis by Scale of Operation, 2023-2035
11.4.5. Aseptic Fill Finish Manufacturing Market for Biologics: Analysis by Company Size, 2023-2035
11.4.6. Aseptic Fill Finish Manufacturing Market for Biologics: Analysis by Geography, 2023-2035
11.5. Aseptic Fill Finish Manufacturing Market for Small Molecules, 2023-2035
11.5.1. Aseptic Fill Finish Manufacturing Market for Small Molecules: Analysis by Type of Packaging Container Offered, 2023-2035
11.5.2. Aseptic Fill Finish Manufacturing Market for Small Molecules: Analysis by Scale of Operation, 2023-2035
11.5.3. Aseptic Fill Finish Manufacturing Market for Small Molecules: Analysis by Company Size, 2023-2035
11.5.4. Aseptic Fill Finish Manufacturing Market for Small Molecules: Analysis by Geography, 2023-2035

12. CASE STUDY: ROBOTICS IN PHARMACEUTICAL PACKAGING
12.1. Chapter Overview
12.2. Role of Robotic Systems in Pharmaceutical Industry
12.3. Role of Robotic Systems in Fill / Finish Operation
12.3.1. Types of Robots Used in Pharmaceutical Operations
12.3.2. Advantages Associated with Robotic Systems
12.3.3. Disadvantages Associated with Robotic Systems
12.4.2. Key Considerations for Selecting a Robotic System
12.3. Contract Service Providers: List of Fill Finish Equipment
12.5. Companies Providing Robots for Use in the Pharmaceutical Industry
12.6. Companies Providing Isolator based Aseptic Filling Systems
12.7. Concluding Remarks

13. CASE STUDY: READY-TO-USE PACKAGING COMPONENTS FOR ASEPTIC FILL FINISH
13.1. Chapter Overview
13.2. Role of Ready-to-Use Packaging Components in Aseptic Fill Finish Operations
13.2.1. Advantages of Ready to Use Packaging Components
13.2.2. Disadvantages of Ready to Use Packaging Components
13.3. Companies Providing Ready to Use Packaging Components
13.4. Concluding Remarks

14. CONCLUDING REMARKS

15. EXECUTIVE INSIGHTS
15.1 Chapter Overview
15.2 IDT Biologika
15.2.1. Company Snapshot
15.2.1. Interview Transcript: Gregor Kawaletz, Former Chief Commercial Officer
15.3 Cytovance Biologics
15.3.1. Company Snapshot
15.3.2. Interview Transcript: Matt Delaney, Former Vice President of Business Development and Marketing
15.4. Syngene
15.4.1. Company Snapshot
15.4.2. Interview Transcript: Purushottam Singnurkar, Vice President and Head of Formulation Development
15.5 oncomed manufacturing
15.5.1. Company Snapshot
15.5.2. Interview Transcript: Ales Sima, Head of Business Development
15.6 Yposkesi
15.6.1. Company Snapshot
15.6.2. Interview Transcript: Amit, Former Technology Watch Manager
15.7 HALIX
15.7.1. Company Snapshot
15.7.2. Interview Transcript: Jos Vergeest, International Business Developer

16. APPENDIX 1: TABULATED DATA

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Market Landscape of Biologics Fill Finish Service Providers
Figure 2.2 Executive Summary: Market Landscape of Small Molecules Fill Finish Service Providers
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Market Forecast and Opportunity Analysis
Figure 3.1 Types of Third-Party Service Providers
Figure 3.2 Commonly Outsourced Fill Finish Operations
Figure 3.3 Steps Involved in Aseptic Fill Finish Process
Figure 3.4 Blow-Fill-Seal Process
Figure 3.5 Key Considerations for Selecting a CMO Partner
Figure 3.6 Risks and Challenges Associated with Outsourcing Aseptic Fill Finish Operations
Figure 4.1 Aseptic Fill Finish Service Providers: Distribution by Year of Establishment
Figure 4.2 Aseptic Fill Finish Service Providers: Distribution by Company Size
Figure 4.3 Aseptic Fill Finish Service Providers: Distribution by Location of Headquarters
Figure 4.4 Aseptic Fill Finish Service Providers: Distribution by Type of Molecule(s)
Figure 4.5 Aseptic Fill Finish Service Providers: Distribution by Type of Packaging Container(s) Offered
Figure 5.1 Biologics Fill Finish Service Providers: Distribution by Year of Establishment
Figure 5.2 Biologics Fill Finish Service Providers: Distribution by Company Size
Figure 5.3 Biologics Fill Finish Service Providers: Distribution by Location of Headquarters
Figure 5.4 Biologics Fill Finish Service Providers: Distribution by Location of Fill Finish Facilities
Figure 5.5 Biologics Fill Finish Service Providers: Distribution by Type of Packaging Container(s) Offered
Figure 5.6 Biologics Fill Finish Service Providers: Distribution by Type of Packaging Container(s) Offered and Type of Drug Product(s) Involved
Figure 5.7 Biologics Fill Finish Service Providers: Distribution by Scale of Operation
Figure 5.8 Biologics Fill Finish Service Providers: Distribution by Additional Drug Product-related Services Offered
Figure 6.1 Small Molecules Fill Finish Service Providers: Distribution by Year of Establishment
Figure 6.2 Small Molecules Fill Finish Service Providers: Distribution by Company Size
Figure 6.3 Small Molecules Fill Finish Service Providers: Distribution by Location of Headquarters
Figure 6.4 Small Molecules Fill Finish Service Providers: Distribution by Location of Fill / Finish Facilities
Figure 6.5 Small Molecules Fill Finish Service Providers: Distribution by Type of Filling Service(s) Offered
Figure 6.6 Small Molecules Fill Finish Service Providers: Distribution by Type of Finishing Service(s) Offered
Figure 6.7 Small Molecules Fill Finish Service Providers: Distribution by Type of Packaging Container(s) Offered
Figure 6.8 Small Molecules Fill Finish Service Providers: Distribution by Scale of Operation
Figure 6.9 Small Molecules Fill Finish Service Providers: Distribution by Type of Dosage Form(s) Filled
Figure 6.10 Small Molecules Fill Finish Service Providers: Distribution by Type of Process(es)
Figure 7.1 AbbVie: Annual Revenues, 2017-H1 2022 (USD Billion)
Figure 7.2 Baxter (a parent company of BioPharma Solutions): Annual Revenues, 2017-H1 2022 (USD Billion)
Figure 7.3 Merck (a parent company of BioReliance): Annual Revenues, 2017-H1 2022 (EUR Billion)
Figure 7.4 Catalent Biologics: Annual Revenues, FY 2017-FY 2022 (USD Billion)
Figure 7.5 Charles River Laboratories: Annual Revenues, 2017-H1 2022 (USD Billion)
Figure 7.6 Thermo Fisher Scientific (a parent company of Patheon): Annual Revenues, 2017-H1 2022 (USD Billion)
Figure 7.7 Pfizer CentreOne: Annual Revenues, 2017-9M 2022 (USD Million)
Figure 8.1 Boehringer Ingelheim (a parent company of Boehringer Ingelheim BioXcellence): Annual Revenues, 2017-H1 2022 (EUR Billion)
Figure 8.2 GlaxoSmithKline: Annual Revenues, 2017 –H1 2022 (GBP Billion)
Figure 8.3 Lonza: Annual Revenues, 2017-H1 2022 (CHF Billion)
Figure 8.4 Pierre Fabre: Annual Revenues, 2018- 2021 (EUR Billion)
Figure 8.5 Wacker Chemie ( a parent company of Wacker Biotech): Annual Revenues, 2017-H1 2022 (EUR Billion)
Figure 8.6 Aenova: Annual Revenues, 2018-2021 (EUR Million)
Figure 8.7 Fresenius Kabi: Annual Revenues, 2017-9M 2022 (EUR Billion)
Figure 8.8 Recipharm: Annual Revenues, 2017- 2020 (SEK Billion)
Figure 8.9 Recipharm: Revenues by Business Divisions, 2020 (SEK Billion)
Figure 9.1 Asymchem: Annual Revenues, 2017-2020 (USD Billion)
Figure 9.2 Samsung Biologics: Annual Revenues, 2017-H1 2022 (KRW Billion)
Figure 9.3 Syngene: Annual Revenues, FY 2017-FY 2022 (INR Million)
Figure 9.4 Takara Bio: Annual Revenues, FY 2017-FY 2022 (JPY Billion)
Figure 9.5 WuXi Biologics: Annual Revenues, 2017-H1 2022 (RMB Million)
Figure 9.6 Siegfried: Annual Revenues, 2017-H1 2022 (CHF Million)
Figure 9.7 Wockhardt: Annual Revenues, FY 2017- FY Q1 2023 (INR Billion)
Figure 10.1 Partnerships and Collaborations: Cumulative Year wise Trend, 2013-2022
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Distribution by Scale of Operation
Figure 10.4 Partnerships and Collaborations: Distribution by Type of Molecule(s) Involved
Figure 10.5 Partnerships and Collaborations: Distribution by Type of Service(s) Offered
Figure 10.6 Partnerships and Collaborations: Distribution by Type of Process(es) Involved
Figure 10.7 Partnerships and Collaborations: Distribution by Type of Drug Product(s) Involved
Figure 10.8 Most Active Players: Distribution by Number of Partnerships
Figure 10.9 Partnerships and Collaborations: Distribution by Geography
Figure 10.10 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 11.1 Global Aseptic Fill Finish Manufacturing Market, 2023-2035 (USD Billion)
Figure 11.2 Aseptic Fill Finish Manufacturing Market: Distribution by Type of Molecule, 2023-2035 (USD Billion)
Figure 11.3 Aseptic Fill Finish Manufacturing Market: Distribution by Type of Packaging Container Offered, 2023-2035 (USD Billion)
Figure 11.4 Aseptic Fill Finish Manufacturing Market: Distribution by Type of Drug Product, 2023-2035 (USD Billion)
Figure 11.5 Aseptic Fill Finish Manufacturing Market: Distribution by Target Therapeutic Area, 2023-2035 (USD Billion)
Figure 11.6 Aseptic Fill Finish Manufacturing Market: Distribution by Scale of Operation, 2023-2035 (USD Billion)
Figure 11.7 Aseptic Fill Finish Manufacturing Market: Distribution by Company Size, 2023-2035 (USD Billion)
Figure 11.8 Aseptic Fill Finish Manufacturing Market: Distribution by Geography, 2023-2035 (USD Billion)
Figure 11.9 Aseptic Fill Finish Manufacturing Market for Biologics, 2023-2035 (USD Billion)
Figure 11.10 Aseptic Fill Finish Manufacturing Market for Biologics: Distribution by Type of Packaging Container Offered, 2023-2035 (USD Billion)
Figure 11.11 Aseptic Fill Finish Manufacturing Market for Biologics: Distribution by Type of Drug Product, 2023-2035 (USD Billion)
Figure 11.12 Aseptic Fill Finish Manufacturing Market for Biologics: Distribution by Target Therapeutic Area, 2023-2035 (USD Billion)
Figure 11.13 Aseptic Fill Finish Manufacturing Market for Biologics: Distribution by Scale of Operation, 2023-2035 (USD Billion)
Figure 11.14 Aseptic Fill Finish Manufacturing Market for Biologics: Distribution by Company Size, 2023-2035 (USD Billion)
Figure 11.15 Aseptic Fill Finish Manufacturing Market for Biologics: Distribution by Geography, 2023-2035 (USD Billion)
Figure 11.16 Aseptic Fill Finish Manufacturing Market for Small Molecules, 2023-2035 (USD Billion)
Figure 11.17 Aseptic Fill Finish Manufacturing Market for Small Molecules: Distribution by Type of Packaging Container Offered, 2023-2035 (USD Billion)
Figure 11.18 Aseptic Fill Finish Manufacturing Market for Small Molecules: Distribution by Scale of Operation, 2023-2035 (USD Billion)
Figure 11.19 Aseptic Fill Finish Manufacturing Market for Small Molecules: Distribution by Company Size, 2023-2035 (USD Billion)
Figure 11.20 Aseptic Fill Finish Manufacturing Market for Small Molecules: Distribution by Geography, 2023-2035 (USD Billion)
Figure 12.1 Key Considerations for Selecting a Robotic System
Figure 12.2 Advantages of Robotic Systems in Pharmaceutical Operations
Figure 13.1 Key Drivers of Ready-to-Use Platform
Figure 14.1 Concluding Remarks: Current Biologic Fill Finish Service Providers Market Landscape
Figure 14.2 Concluding Remarks: Current Small Molecule Fill / Finish Service Providers Market Landscape
Figure 14.3 Concluding Remarks: Partnerships and Collaborations
Figure 14.4 Concluding Remarks: Market Sizing and Opportunity Analysis

List Of Tables

Table 4.1 Aseptic Fill Finish Service Providers: List of Companies
Table 4.2 Aseptic Fill Finish Service Providers: Information on Type of Packaging Container(s) Offered
Table 5.1 Biologics Fill Finish Service Providers: List of Companies
Table 5.2 Biologics Fill Finish Service Providers: Information on Type of Packaging Container(s) Offered
Table 5.3 Biologics Fill Finish Service Providers: Information on Type of Drug Product(s) Involved
Table 5.4 Biologics Fill Finish Service Providers: Information on Scale of Operation
Table 5.5 Biologics Fill Finish Service Providers: Information on Additional Drug Product-related Services Offered
Table 5.6 Biologics Fill Finish Service Providers: Information on Fill Finish Capacity
Table 6.1 Small Molecules Fill Finish Service Providers: List of Companies
Table 6.2 Small Molecules Fill Finish Service Providers: Information on Fill Finish Technique
Table 6.3 Small Molecules Fill Finish Service Providers: Information on Type of Packaging Container(s) Offered
Table 6.4 Small Molecules Fill Finish Service Providers: Information on Scale of Operation
Table 6.5 Small Molecules Fill Finish Service Providers: Information on Type of Dosage Form(s) Filled and Type of Process(es)
Table 6.6 Small Molecules Fill Finish Service Providers: Information on Fill Finish Capacity
Table 7.1 Biologics Fill Finish Service Providers: List of Companies Profiled
Table 7.2 AbbVie Contract Manufacturing: Company Snapshot
Table 7.3 AbbVie Contract Manufacturing: Service Portfolio
Table 7.4 AbbVie Contract Manufacturing: Fill Finish Manufacturing
Table 7.5 AbbVie Contract Manufacturing: Sterile Manufacturing Facilities
Table 7.6 AbbVie Contract Manufacturing: Recent Developments and Future Outlook
Table 7.7 BioPharma Solutions: Company Snapshot
Table 7.8 BioPharma Solutions: Service Portfolio
Table 7.9 BioPharma Solutions: Fill Finish Manufacturing
Table 7.10 BioPharma Solutions: Sterile Manufacturing Facilities
Table 7.11 BioPharma Solutions: Recent Developments and Future Outlook
Table 7.12 BioReliance: Company Snapshot
Table 7.13 BioReliance: Service Portfolio
Table 7.14 BioReliance: Fill Finish Manufacturing
Table 7.15 BioReliance: Sterile Manufacturing Facilities
Table 7.16 BioReliance: Recent Developments and Future Outlook
Table 7.17 Catalent Biologics: Company Snapshot
Table 7.18 Catalent Biologics: Service Portfolio
Table 7.19 Catalent Biologics: Fill Finish Manufacturing
Table 7.20 Catalent Biologics: Sterile Manufacturing Facilities
Table 7.21 Catalent Biologics: Recent Developments and Future Outlook
Table 7.22 Charles River Laboratories: Company Snapshot
Table 7.23 Charles River Laboratories: Fill Finish Manufacturing
Table 7.24 Charles River Laboratories: Sterile Manufacturing Facilities
Table 7.25 Charles River Laboratories: Recent Developments and Future Outlook
Table 7.26 Patheon: Company Snapshot
Table 7.27 Patheon: Service Portfolio
Table 7.28 Patheon: Fill Finish Manufacturing
Table 7.29 Patheon: Recent Developments and Future Outlook
Table 7.30 Small Molecules Fill Finish Service Providers: List of Companies Profiled
Table 7.31 Pfizer CentreOne: Company Snapshot
Table 7.32 Pfizer CentreOne: Service Portfolio
Table 7.33 Pfizer CentreOne: Fill Finish Manufacturing
Table 7.34 Pfizer CentreOne: Recent Developments and Future Outlook
Table 7.35 Plastikon Healthcare: Company Snapshot
Table 7.36 Plastikon Healthcare: Service Portfolio
Table 7.37 Plastikon Healthcare: Fill Finish Manufacturing
Table 7.38 Sharp Services: Company Snapshot
Table 7.39 Sharp Services: Service Portfolio
Table 7.40 Sharp Services: Fill Finish Manufacturing
Table 7.41 Sharp Services: Recent Developments and Future Outlook
Table 8.1 Biologics Fill / Finish Service Providers in Europe: List of Companies Profiled
Table 8.2 Boehringer Ingelheim BioXcellence: Company Snapshot
Table 8.3 Boehringer Ingelheim BioXcellence: Service Portfolio
Table 8.4 Boehringer Ingelheim BioXcellence: Fill Finish Manufacturing
Table 8.5 Boehringer Ingelheim BioXcellence: Sterile Manufacturing Facilities
Table 8.6 Boehringer Ingelheim BioXcellence: Recent Developments and Future Outlook
Table 8.7 Fareva: Company Snapshot
Table 8.8 Fareva: Fill Finish Manufacturing
Table 8.9 Fareva: Recent Developments and Future Outlook
Table 8.10 Glaxo SmithKline: Company Snapshot
Table 8.11 Glaxo SmithKline: Fill Finish Manufacturing
Table 8.12 Glaxo SmithKline: Recent Developments and Future Outlook
Table 8.13 Lonza: Company Snapshot
Table 8.14 Lonza: Service Portfolio
Table 8.15 Lonza: Fill Finish Manufacturing
Table 8.16 Lonza: Recent Developments and Future Outlook
Table 8.17 Pierre Fabre: Company Snapshot
Table 8.18 Pierre Fabre: Service Portfolio
Table 8.19 Pierre Fabre: Fill Finish Manufacturing
Table 8.20 Pierre Fabre: Sterile Manufacturing Facilities
Table 8.21 Pierre Fabre: Recent Developments and Future Outlook
Table 8.22 Wacker Biotech: Company Snapshot
Table 8.23 Wacker Biotech: Service Portfolio
Table 8.24 Wacker Biotech: Fill Finish Manufacturing
Table 8.25 Wacker Biotech: Sterile Manufacturing Facilities
Table 8.26 Wacker Biotech: Recent Developments and Future Outlook
Table 8.27 Small Molecules Fill Finish Service Providers in Europe: List of Companies Profiled
Table 8.28 Aenova: Company Snapshot
Table 8.29 Aenova: Service Portfolio
Table 8.30 Aenova: Fill Finish Manufacturing
Table 8.31 Aenova: Recent Developments and Future Outlook
Table 8.32 APL: Company Snapshot
Table 8.33 APL: Service Portfolio
Table 8.34 APL: Fill Finish Manufacturing
Table 8.35 CordenPharma: Company Snapshot
Table 8.36 CordenPharma: Service Portfolio
Table 8.37 CordenPharma: Fill Finish Manufacturing
Table 8.38 CordenPharma: Recent Developments and Future Outlook
Table 8.39 Delpharm: Company Snapshot
Table 8.40 Delpharm: Service Portfolio
Table 8.41 Delpharm: Fill Finish Manufacturing
Table 8.42 Delpharm: Recent Developments and Future Outlook
Table 8.43 PiSA Farmaceutica: Company Snapshot
Table 8.44 PiSA Farmaceutica: Fill Finish Manufacturing
Table 8.45 Biologics and Small Molecules Fill Finish Service Providers in Europe: List of Companies Profiled
Table 8.46 Fresenius Kabi: Company Snapshot
Table 8.47 Fresenius Kabi: Fill Finish Manufacturing
Table 8.48 Recipharm: Company Snapshot
Table 8.49 Recipharm: Service Portfolio
Table 8.50 Recipharm: Fill Finish Manufacturing
Table 8.51 Recipharm: Recent Developments and Future Outlook
Table 9.1 Biologics Fill Finish Service Providers in Asia-Pacific: List of Companies Profiled
Table 9.2 Asymchem: Company Snapshot
Table 9.3 Asymchem: Service Portfolio
Table 9.4 Asymchem: Fill Finish Manufacturing
Table 9.5 Asymchem: Sterile Manufacturing Facilities
Table 9.6 Asymchem: Recent Developments and Future Outlook
Table 9.7 Samsung Biologics: Company Snapshot
Table 9.8 Samsung Biologics: Service Portfolio
Table 9.9 Samsung Biologics: Fill Finish Manufacturing
Table 9.10 Samsung Biologics: Recent Developments and Future Outlook
Table 9.11 Syngene: Company Snapshot
Table 9.12 Syngene: Service Portfolio
Table 9.13 Syngene: Fill Finish Manufacturing
Table 9.14 Syngene: Recent Developments and Future Outlook
Table 9.15 Takara Bio: Company Snapshot
Table 9.16 Takara Bio: Service Portfolio
Table 9.17 Takara Bio: Fill Finish Manufacturing
Table 9.18 Takara Bio: Recent Developments and Future Outlook
Table 9.19 WuXi Biologics: Company Snapshot
Table 9.20 WuXi Biologics: Services Portfolio
Table 9.21 Wuxi Biologics: Fill Finish Manufacturing
Table 9.22 WuXi Biologics: Sterile Manufacturing Facilities
Table 9.23 WuXi Biologics: Recent Developments and Future Outlook
Table 9.24 Hetero Drugs: Company Snapshot
Table 9.25 Hetero Drugs: Fill Finish Manufacturing
Table 9.26 Intas Pharmaceuticals: Company Snapshot
Table 9.27 Intas Pharmaceuticals: Fill Finish Manufacturing
Table 9.28 Small Molecules Fill / Finish Service Providers in Asia-Pacific: List of Companies Profiled
Table 9.29 Siegfried: Company Snapshot
Table 9.30 Siegfried: Service Portfolio
Table 9.31 Siegfried: Fill Finish Manufacturing
Table 9.32 Siegfried: Recent Developments and Future Outlook
Table 9.33 Wockhardt: Company Snapshot
Table 9.34 Wockhardt: Fill Finish Manufacturing
Table 9.35 Wockhardt: Recent Developments and Future Outlook
Table 10.1 Aseptic Fill Finish Service Providers: Partnerships and Collaborations
Table 10.2 Partnerships and Collaborations: Information on Type of Molecule(s) Involved and Type of Service(s) Offered
Table 10.3 Partnerships and Collaborations: Information on Type of Drug Product(s) Involved and Type of Process(es) Involved
Table 12.1 Contract Service Providers: Information on Fill Finish Equipment
Table 12.2 List of Pharmaceutical Robotics Manufacturers
Table 12.3 Isolator based Aseptic Filling Systems: Information on Compatible Primary Container
Table 13.1 List of Companies Supplying Ready-to-Use Aseptic Packaging Components
Table 16.1 Aseptic Fill Finish Service Providers: Distribution by Year of Establishment
Table 16.2 Aseptic Fill Finish Service Providers: Distribution by Company Size
Table 16.3 Aseptic Fill Finish Service Providers: Distribution by Location of Headquarters
Table 16.4 Aseptic Fill Finish Service Providers: Distribution by Type of Molecule(s)
Table 16.5 Aseptic Fill Finish Service Providers: Distribution by Type of Packaging Container(s) Offered
Table 16.6 Biologics Fill Finish Service Providers: Distribution by Year of Establishment
Table 16.7 Biologics Fill Finish Service Providers: Distribution by Company Size
Table 16.8 Biologics Fill Finish Service Providers: Distribution by Location of Headquarters
Table 16.9 Biologics Fill Finish Service Providers: Distribution by Location of Fill Finish Facilities
Table 16.10 Biologics Fill Finish Service Providers: Distribution by Type of Packaging Container(s) Offered
Table 16.11 Biologics Fill Finish Service Providers: Distribution by Type of Packaging Container(s) Offered and Type of Drug Product(s) Involved
Table 16.12 Biologics Fill Finish Service Providers: Distribution by Scale of Operation
Table 16.13 Biologics Fill Finish Service Providers: Distribution by Additional Drug Product-related Services Offered
Table 16.14 Small Molecules Fill Finish Service Providers: Distribution by Year of Establishment
Table 16.15 Small Molecules Fill Finish Service Providers: Distribution by Company Size
Table 16.16 Small Molecules Fill Finish Service Providers: Distribution by Location of Headquarters
Table 16.17 Small Molecules Fill Finish Service Providers: Distribution by Location of Fill Finish Facilities
Table 16.18 Small Molecules Fill Finish Service Providers: Distribution by Type of Filling Service(s) Offered
Table 16.19 Small Molecules Fill Finish Service Providers: Distribution by Type of Finishing Service(s) Offered
Table 16.19 Small Molecules Fill Finish Service Providers: Distribution by Type of Packaging Container(s) Offered
Table 16.20 Small Molecules Fill Finish Service Providers: Distribution by Scale of Operation
Table 16.21 Small Molecules Fill Finish Service Providers: Distribution by Type of Dosage Form(s) Filled
Table 16.22 Small Molecules Fill Finish Service Providers: Distribution by Type of Process(es)
Table 16.23 AbbVie: Annual Revenues, 2017-H1 2022 (USD Billion)
Table 16.24 Baxter (a parent company of BioPharma Solutions): Annual Revenues, 2017-H1 2022 (USD Billion)
Table 16.25 Merck (a parent company of BioReliance): Annual Revenues, 2017-H1 2022 (EUR Billion)
Table 16.26 Catalent Biologics: Annual Revenues, FY 2017-FY 2022 (USD Billion)
Table 16.27 Charles River Laboratories: Annual Revenues, 2017-H1 2022 (USD Billion)
Table 16.28 Thermo Fisher Scientific (a parent company of Patheon): Annual Revenues, 2017-H1 2022 (USD Billion)
Table 16.29 Pfizer CentreOne: Annual Revenues, 2017-9M 2022 (USD Million)
Table 16.30 Boehringer Ingelheim (a parent company of Boehringer Ingelheim BioXcellence): Annual Revenues, 2017-H1 2022 (EUR Billion)
Table 16.31 GlaxoSmithKline: Annual Revenues, 2017 –H1 2022 (GBP Billion)
Table 16.32 Lonza: Annual Revenues, 2017-H1 2022 (CHF Billion)
Table 16.33 Pierre Fabre: Annual Revenues, 2018- 2021 (EUR Billion)
Table 16.34 Wacker Chemie ( a parent company of Wacker Biotech): Annual Revenues, 2017-H1 2022 (EUR Billion)
Table 16.35 Aenova: Annual Revenues, 2018-2021 (EUR Million)
Table 16.36 Fresenius Kabi: Annual Revenues, 2017-9M 2022 (EUR Billion)
Table 16.37 Recipharm: Annual Revenues, 2017- 2020 (SEK Billion)
Table 16.38 Recipharm: Revenues by Business Divisions, 2020 (SEK Billion)
Table 16.39 Asymchem: Annual Revenues, 2017-2020 (USD Billion)
Table 16.40 Samsung Biologics: Annual Revenues, 2017-H1 2022 (KRW Billion)
Table 16.41 Syngene: Annual Revenues, FY 2017-FY 2022 (INR Million)
Table 16.42 Takara Bio: Annual Revenues, FY 2017-FY 2022 (JPY Billion)
Table 16.43 WuXi Biologics: Annual Revenues, 2017-H1 2022 (RMB Million)
Table 16.44 Siegfried: Annual Revenues, 2017-H1 2022 (CHF Million)
Table 16.45 Wockhardt: Annual Revenues, FY 2017- FY Q1 2023 (INR Billion)
Table 16.46 Partnerships and Collaborations: Cumulative Year wise Trend, 2013-2022
Table 16.47 Partnerships and Collaborations: Distribution by Type of Partnership
Table 16.48 Partnerships and Collaborations: Distribution by Scale of Operation
Table 16.49 Partnerships and Collaborations: Distribution by Type of Molecule(s) Involved
Table 16.50 Partnerships and Collaborations: Distribution by Type of Service(s) Offered
Table 16.51 Partnerships and Collaborations: Distribution by Type of Process(es) Involved
Table 16.52 Partnerships and Collaborations: Distribution by Type of Drug Product(s) Involved
Table 16.53 Most Active Players: Distribution by Number of Partnerships
Table 16.54 Partnerships and Collaborations: Distribution by Geography
Table 16.55 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 16.56 Global Aseptic Fill Finish Manufacturing Market, 2023-2035 (USD Billion)
Table 16.57 Aseptic Fill Finish Manufacturing Market, Conservative, Base and Optimistic Scenarios: Distribution by Type of Molecule, 2023-2035 (USD Billion)
Table 16.58 Aseptic Fill Finish Manufacturing Market, Conservative, Base and Optimistic Scenarios: Distribution by Type of Packaging Container Offered, 2023-2035 (USD Billion)
Table 16.59 Aseptic Fill Finish Manufacturing Market, Conservative, Base and Optimistic Scenarios: Distribution by Type of Drug Product, 2023-2035 (USD Billion)
Table 16.60 Aseptic Fill Finish Manufacturing Market, Conservative, Base and Optimistic Scenarios: Distribution by Target Therapeutic Area, 2023-2035 (USD Billion)
Table 16.61 Aseptic Fill Finish Manufacturing Market, Conservative, Base and Optimistic Scenarios: Distribution by Scale of Operation, 2023-2035 (USD Billion)
Table 16.62 Aseptic Fill Finish Manufacturing Market, Conservative, Base and Optimistic Scenarios: Distribution by Company Size, 2023-2035 (USD Billion)
Table 16.63 Aseptic Fill Finish Manufacturing Market, Conservative, Base and Optimistic Scenarios: Distribution by Geography, 2023-2035 (USD Billion)
Table 16.64 Aseptic Fill Finish Manufacturing Market for Biologics, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 16.65 Aseptic Fill Finish Manufacturing Market for Biologics, Conservative, Base and Optimistic Scenarios: Distribution by Type of Packaging Container Offered, 2023-2035 (USD Billion)
Table 16.66 Aseptic Fill Finish Manufacturing Market for Biologics, Conservative, Base and Optimistic Scenarios: Distribution by Type of Drug Product, 2023-2035 (USD Billion)
Table 16.67 Aseptic Fill Finish Manufacturing Market for Biologics, Conservative, Base and Optimistic Scenarios: Distribution by Target Therapeutic Area, 2023-2035 (USD Billion)
Table 16.68 Aseptic Fill Finish Manufacturing Market for Biologics, Conservative, Base and Optimistic Scenarios: Distribution by Scale of Operation, 2023-2035 (USD Billion)
Table 16.69 Aseptic Fill Finish Manufacturing Market for Biologics, Conservative, Base and Optimistic Scenarios: Distribution by Company Size, 2023-2035 (USD Billion)
Table 16.70 Aseptic Fill Finish Manufacturing Market for Biologics, Conservative, Base and Optimistic Scenarios: Distribution by Geography, 2023-2035 (USD Billion)
Table 16.71 Aseptic Fill Finish Manufacturing Market for Small Molecules, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 16.72 Aseptic Fill Finish Manufacturing Market for Small Molecules, Conservative, Base and Optimistic Scenarios: Distribution by Type of Packaging Container Offered, 2023-2035 (USD Billion)
Table 16.73 Aseptic Fill Finish Manufacturing Market for Small Molecules, Conservative, Base and Optimistic Scenarios: Distribution by Scale of Operation, 2023-2035 (USD Billion)
Table 16.74 Aseptic Fill Finish Manufacturing Market for Small Molecules, Conservative, Base and Optimistic Scenarios: Distribution by Company Size, 2023-2035 (USD Billion)
Table 16.75 Aseptic Fill Finish Manufacturing Market for Small Molecules, Conservative, Base and Optimistic Scenarios: Distribution by Geography, 2023-2035 (USD Billion)

List Of Companies

The following companies and organizations have been mentioned in the report:

3P Biopharmaceuticals
Aalto Scientific
ABB
AbbVie
AbbVie Contract Manufacturing
AbTis
Abzena
ACG
ACIC Pharmaceutical Machinery
AdaptVac
ADC Biotechnology
Adimmune
Advanced BioScience Laboratories
Aenova
Affinity Life Sciences
Afton Scientific
Agilis Biotherapeutics
AJ Biologics
Ajinomoto Bio-Pharma
Akorn
Akron Biotech
Akso Biopharmaceutical
Akums Drugs & Pharmaceuticals
Alanza
Alcami (Acquired by GHO Capital and The Vistria Group)
Alcon
Aldevron
Alkermes
Allergy Laboratories
Althea
Amatsigroup
Ambica Pharma Machines
Amgen
Amicus Therapeutics
Amsino International
Anchiano Therapeutics (formerly known as BioCanCell)
Anchor Mark
Anthos Therapeutics
apceth Biopharma
APG Europe
ApiJect Systems
APL
Aptar Pharma
Aptuit
Arabio
ARaymond Life
Arch Biopartners
Argonaut Manufacturing Services
ARISTO Pharmaceuticals
Ascendia Pharmaceuticals
Asept Pak
Aseptic Technologies
Asklepios BioPharmaceutical
AST
AstraZeneca
Asymchem
Ausia Biotech
Austrianova
Automated Systems of Tacoma
Avara Pharmaceutical Services
Avid Bioservices
Avrio Biopharmaceuticals
AWS Bio-Pharma Technologies
Axcellerate Pharma
B. Braun’s OEM Division
Baccinex
Basic Pharma
Bausch & Ströbel
BAUSCH Advanced Technology (BATG)
Baxter BioPharma Solutions
Bayer
BD
BePharBel Manufacturing
Berkshire Sterile Manufacturing
Binex
Bio Elpida
Bio-Concept Laboratories
BioConnection
Biofabri
Biogen
BioMARC
Biomay
Biomedical Advanced Research and Development Authority (BARDA)
BioNTech
BioPharma Solutions
BioReliance
Bio-Serv
BioSkryb Genomics
BioTechLogic
BioTechnique
Biovian
BirgiMefar
Boehringer Ingelheim BioXcellence
Bolt Biotherapeutics
Bosch Packaging Technology
Boston Children’s Hospital
Bristol-Myers Squibb
Bryllan
BSP Pharmaceuticals
Burrard Pharmaceuticals
Bushu Pharmaceuticals
Cangene Corporation (Acquired by Emergent BioSolutions)
Canton Biologics
Capmatic
CARBOGEN AMCIS
Carlyle
Catalent Biologics
Catalent Pharma Solutions
Celgene
Cell Culture Company
Cellin Technologies
Celonic
Celsee
Cenexi
Cerbios-Pharma
Cerium Pharmaceuticals
Chase-Logeman
Chemigran
ChemPartner
Chime Biologics
China Gateway Biologics
CinnaGen
Cirondrugs
Citryll
CMAB Biopharma
CMC Biologics
CMIC CMO
Coalition for the Promotion of Innovations for Epidemic Preparedness (CEPI)
Cobra Biologics
C.O.C. Farmaceutici
Cognate BioServices
Cognitus Consulting
Coldstream Laboratories
Colorado State University
Columbus Venture Partners
Comecer
Concord Drugs
Cook Pharmica
CordenPharma
Cozzoli Machine Company
Creative Biolabs
CreoSalus
Crystal Pharma
CureVac
Curida
CytoDyn
Cytovance Biologics
Daikyo Seiko
Dalton Pharma Services
Dara Pharma
Datwyler Sealing Solutions
Delpharm
DENSO
Dhruv Life Sciences
Disposable Lab
DM Bio
Drugs for Neglected Disease Initiative (DNDi)
DSM Pharmaceutical Products
DWK Life Sciences
EirGen Pharma
EirGenix
Eli Lilly
EMA Pharmaceuticals
EMCM
Emcure Pharmaceuticals
Emergent BioSolutions
Esco Aster
Etinpro
EuBiologics
EUCODIS Bioscience
Eurofins
Eurofins BioPharma Product Testing Netherlands (EBPT NL)
Euro-Med Laboratories
EVER Pharma
Evonik Health Care
ExCellThera
Exelead
Experic
Extract Technology
FANUC America
Fareva
FinVector
Flamingo Pharmaceuticals
Formosa Laboratories
Fresenius Kabi Contract Manufacturing
Früh Verpackungstechnik
FUJIFILM Diosynth Biotechnologies
GC Pharma
GEA
Gebro Pharma
Genentech
GeneQuantum Healthcare
Generic Specialities
GenIbet Biopharmaceuticals
Genovior Biotech
Genprex
Gerresheimer
Getinge
GigaGen
Gilead
Gland Pharma
GLyPharma
Goodwin Biotechnology
GP Pharm
Grand River Aseptic Manufacturing
groninger
GSK
GTCR
Gulf Biotech
HALIX
hameln pharma
Handl Therapeutics
Hanford Pharmaceuticals
Hansa Biopharma
Hapten Sciences
Health Biotech
Healthcare Pharmaceuticals
Healthy Life Pharma
Hepalink
Hetero Drugs
Hisun Pharmaceuticals USA
HOOKIPA Pharma
Horizon Therapeutics
Hospira (Acquired by Pfizer)
Humanigen
Hybio Pharmaceutical
Hycult Biotech
iBio
IDT Australia
IDT Biologika
IMA Group
Immune Pharmaceuticals
Immunex
INCOG BioPharma Services
Indicia
Industria Macchine Automatiche (IMA)
Infectious Disease Research Institute
Injectalia (A subsidiary of Orofino Pharmaceuticals)
Intas Pharmaceuticals
Integrity Bio
Irvine Pharmaceutical Services
Istituto Biochimico Italiano Giovanni Lorenzini
Janssen Pharmaceuticals
JHL Biotech
Jiangsu Yaohai Bio-pharmaceutical
Johnson & Johnson
JOINN Biologics
Jubilant HollisterStier
Kanda BioTech
Kaneka Eurogentec
Kawasaki Heavy Industries
Kaysersberg Pharmaceuticals (Acquired by Recipharm)
Kemwell Biopharma
Klenzaids
Kohlberg and Mubadala
KP Pharmaceutical Technology
KUKA
Kymanox
Laboratorios Farmaceuticos ROVI
Laekna Therapeutics
LakePharma
LamKap Bio
Lava Therapeutics
Legacy Pharmaceuticals
LESVI
Lifecore Biomedical
Liof Pharma
Lohmann Pharma Herstellung
Lomapharm
Lonza
Lubrizol
LuinaBio
LyoGen
Lyophilization Services of New England (LSNE) (Acquired by PCI Pharma)
Lyophilization Technology
M&O Perry
MabPlex
MabPlex
Madison Dearborn Partners
Magle Chemoswed
Makcur Laboratories
Marchesini Group
MassBiologics
Massman Automation Designs
MaSTherCell
Masy BioServices
MEDInstill
Merck
Microdermics
Millmount Healthcare (Acquired by PCI Pharma Services)
Miltenyi Biotec
Minaris Regenerative Medicine
Mithra CDMO
Mitsubishi Electric
Moderna
Morgridge Institute for Research (MIR)
Mycenax Biotech
Najít Technologies
National Health Research Institutes (NHRI)
National Institutes of Health
Navesta
NBE Therapeutics
Nephron Pharmaceuticals
Neuma (Acquired by Kymanox)
New Vision Pharmaceuticals
NextPharma
Nikon CeLL innovation
Ningbo Zhengli Pharmaceutical Packing
Nipro PharmaPackaging
Nitto Avecia
n-Lorem Foundation
Northway Biotech
Nova Laboratories
Novartis
Novasep
Novavax
Noveome Biotherapeutics
Novex Innovations
Novo Nordisk
Novocol Pharma
Nykode Therapeutics (formerly known as Vaccibody)
Oakwood Labs
Ology Bioservices
OmniChem
OMRON Industrial Automation
oncomed manufacturing
Oncotec Pharma Produktion
OPKO Health
OPTIMA
Ori Biotech
Orion Corporation
Oryn Therapeutics
OSO Biopharmaceuticals Manufacturing (Acquired by AMRI)
Ottawa Hospital Research Institute
Oxford BioMedica
Pace Analytical
PaizaBio
Pall Life Sciences
Panacea Pharmaceuticals
Panpharma
Paragon Bioservices
Particle Measuring Systems (PMS)
Partners Group
Patheon (Acquired by Thermo Fisher Scientific)
PCI Pharma Services
Penn Pharmaceutical Services
Permira
Pfizer
Pfizer CentreOne
Pharma Stulln
Pharmaceutical Packaging Professionals
Pharmaceutics International
Pharma-Q
Pharmaster
PharmaTher
Pierre Fabre
Pii (Pharmaceutics International Inc.)
Piramal Pharma Solutions
PiSA Farmacéutica
Plastikon Healthcare
PMI BioPharma Solutions
Polfa Tarchomin
Polpharma Biologics
Polymun Scientific
Praxis Pharmaceutical
PrimaPharma
Prince Sterilization Services
PSC Biotech
PYRAMID Laboratories
Quality BioResources
QureBio
Recipharm
Regeneron Pharmaceuticals
Reliance Life Sciences
Renaissance Lakewood
Rentschler Biopharma
Rentschler Fill Solutions
Resilience
Revance Therapeutics
Roche
Romaco
Rommelag CMO
Rompharm
RoslinCT
ROTA Verpackungstechnik
Ruibo Bio-Technology
Russian Direct Investment Fund (RDIF)
Saint-Gobain
Salvat
Sam Chun Dang Pharm
Samsung Bioepis
Samsung Biologics
Sandoz
Sanofi
Saudi Biotechnology Manufacturing
Schematic Engineering Industries
SCHOTT
ScinoPharm
Seiko Epson
Selecta Biosciences
Selkirk Pharma
Sensorion
Sentiss Pharma
BravoBio
Sharp
Shengnuo Peptide
Shenzhen Techdow Pharmaceutical
Sherpa Clinical Packaging (Acquired by PCI Pharma Services)
Shibuya
Shree Bhagwati Machtech
SialoCarb
Siam Bioscience
Siegfried Holding
Singota Solutions
Sio Gene Therapies
SiO2 Medical Products
SIRION Biotech
Sirton Pharmaceuticals
SKAN
Snowbell Machines
Societal CDMO
SP Industries
Spanish Agency of Medicines and Medical Devices (AEMPS)
Square Pharmaceuticals
Staubli
Stelis Biopharma
Steriline
Stevanato
Surrozen
Swissfillon
Symbiosis Pharmaceutical
Symphogen
SynCo Bio Partners
Syngene
Synklino
Syntegon
Sypharma
TAIYO Pharma
Takara Bio
Tanvex BioPharma
Taysha Gene Therapies
Tekpak
ten23 health
Themis Medicare
Therapure Biomanufacturing
Theratechnologies
Thermo Fisher Scientific
Tofflon
Transcoject
TransMedics
TriPharm Services (Acquired by Alcami)
Truking Technology
Tubulis
U.S. Army Contracting Command (ACC)
UCB
Ultragenyx Pharmaceutical
Unicep
Unipharma
Unither Pharmaceuticals
Universal Robots
University of Iowa Pharmaceuticals
University of Queensland
Unolab Manufacturing
USV
Vaccine and Infectious Disease Organization (VIDO)
Vanrx Pharmasystems
Vaxine
VBI Vaccines
Vetter Pharma
VGXI
Vibalogics
Vigene Biosciences
Viralgen
V-nano
VxP Biologics
VxP Pharma
WACKER Biotech
Waisman Biomanufacturing
Watson-Marlow
West Pharmaceutical Services
Wockhardt
WuXi Biologics
Wuxi Fortune Pharmaceutical
Wuxi Griffin
Yaskawa Electric
Yposkesi
Zoetis

Source 1: https://biologics.catalent.com/expert-content/drug-substance-manufacturing/trends-in-biologics-manufacturing-from-drug-substance-to-fill-finish/
Source 2: https://www.pharmtech.com/view/fillfinish-outsourcing

PRICING DETAILS

Single-User License USD 4,799

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

One Location Site License USD 6,999

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

Department License USD 10,599

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

Enterprise License USD 17,999

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com

Aseptic Fill Finish Manufacturing Market

Aseptic Fill Finish Manufacturing Market by Type of Molecule, Type of Packaging Container Offered, Type of Drug Product, Scale of Operation, Company Size, Target Therapeutic Area and Geographical Regions: Industry Trends and Global Forecasts, 2023-2035

Aseptic Fill Finish Manufacturing Market Overview

Key Market Insights

Growing Demand for Aseptic Fill Finish Services

Fill Finish CMO: Need for Outsourcing Aseptic Fill Finish Operations

Sterile Fill Finish: Key Drivers of the Aseptic Fill Finish Manufacturing Market

Current Market Landscape of Aseptic Fill Finish Service Providers

Aseptic Fill Finish Manufacturing: Overall Market Size is Anticipated to Increase at CAGR of ~9%

Key Companies in the Aseptic Fill Finish Manufacturing Market

Recent Developments in Aseptic Fill Finish Market

Scope of the Report

Frequently Asked Questions

Question 1: What is the aseptic fill finish?

Question 2: What are the requirements and considerations for aseptic fill finish operation?

Question 3: How many players are providing aseptic fill finish services?

Question 4: What are the latest trends in aseptic fill finish services market?

Question 5: What is the growth rate of aseptic fill finish services market?

Question 6: Which region captures the largest share of the aseptic fill finish services market?

Question 7: Which segment, in terms of type of molecule, currently accounts for the largest share of the aseptic fill finish services market?

Question 8: Which types of packaging containers are most widely used in the aseptic fill finish services market?

Question 9: What type of partnerships are taking place in the aseptic fill finish services market?

Table Of Contents

List Of Figures

List Of Tables

List Of Companies

Single-User License USD 4,799

One Location Site License USD 6,999

Department License USD 10,599

Enterprise License USD 17,999

The Future Of Healthcare: Wearable Injectors Unveiled

Cannabis Testing / Hemp Testing: Unlocking the Future Opportunities in Healthcare

Market Insights Reports

Indication Specific Reports

Aseptic Fill Finish Manufacturing Market

Aseptic Fill Finish Manufacturing Market by Type of Molecule, Type of Packaging Container Offered, Type of Drug Product, Scale of Operation, Company Size, Target Therapeutic Area and Geographical Regions: Industry Trends and Global Forecasts, 2023-2035

Aseptic Fill Finish Manufacturing Market Overview

Key Market Insights

Growing Demand for Aseptic Fill Finish Services

Fill Finish CMO: Need for Outsourcing Aseptic Fill Finish Operations

Sterile Fill Finish: Key Drivers of the Aseptic Fill Finish Manufacturing Market

Current Market Landscape of Aseptic Fill Finish Service Providers

Aseptic Fill Finish Manufacturing: Overall Market Size is Anticipated to Increase at CAGR of ~9%

Key Companies in the Aseptic Fill Finish Manufacturing Market

Recent Developments in Aseptic Fill Finish Market

Scope of the Report

Frequently Asked Questions

Question 1: What is the aseptic fill finish?

Question 2: What are the requirements and considerations for aseptic fill finish operation?

Question 3: How many players are providing aseptic fill finish services?

Question 4: What are the latest trends in aseptic fill finish services market?

Question 5: What is the growth rate of aseptic fill finish services market?

Question 6: Which region captures the largest share of the aseptic fill finish services market?

Question 7: Which segment, in terms of type of molecule, currently accounts for the largest share of the aseptic fill finish services market?

Question 8: Which types of packaging containers are most widely used in the aseptic fill finish services market?

Question 9: What type of partnerships are taking place in the aseptic fill finish services market?

Table Of Contents

List Of Figures

List Of Tables

List Of Companies

Single-User License USD 4,799

One Location Site License USD 6,999

Department License USD 10,599

Enterprise License USD 17,999

The Future Of Healthcare: Wearable Injectors Unveiled

Cannabis Testing / Hemp Testing: Unlocking the Future Opportunities in Healthcare